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Abstract
BACKGROUND: CT scan provides information about the anato-
my and morphology, may confirm whether the change is single 
or has multifocal character and may suggest the probability of 
malignancy. Due to increased metabolism, at PET examination 
malignant tissues usually show a greater uptake of 18F-FDG than 
benign changes and healthy tissue. In several cases, PET-CT 
is described only by a specialist in nuclear medicine without 
consulting a radiologist. The aim of this study is to evaluate the 
accuracy of PET with assessment performed by a single nuclear 
medicine specialist and multidisciplinary assessment by both 
nuclear medicine and radiology specialists. 
MATERIALS AND METHODS: PET-CT was performed in 58 
consecutive patients referred from John Paul II Hospital in Cra-
cow because of radiologically diagnosed solitary pulmonary 
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nodule (SPN) with diameter > 1 cm. An histopatological speci-
men was obtained in 37 patients. In 17 cases PET-CT images 
were evaluated by a single nuclear medicine specialist (group 
A), while for the remaining 20 cases, the image evaluation was 
performed shoulder-to-shoulder by a nuclear medicine specialist 
and a radiologist (group B).
ANALYSIS OF DATA: Overall PET sensitivity, specificity, positive 
and negative predictive value and accuracy were calculated on 
the basis of anatomopathologic results. These data were also 
calculated separately for groups A and B.
RESULTS: The histopatologic examination demonstrated the 
non neoplastic character of 7/37 lesions. The sensitivity, specific-
ity, accuracy, positive and negative predictive values for group 
A were 85.7%, 100%, 100%, 33.3% and 88% while for group B 
were 92.8%, 83.3%, 92.8%, 83.3% and 90% respectively.
CONCLUSION: PET-CT is an accurate diagnostic method to as-
sess the nature of solitary pulmonary nodules. The consultation 
with radiologist does not substantially affect the PET-CT diagnos-
tic accuracy, but can lead to a higher negative predictive value. 
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Background
Hybrid PET-CT imaging has gained a wide acceptance for 
diagnosing and staging malignancies [1]. The possibility to couple 
the spatial resolution of CT to the molecular imaging of PET is the 
most attractive feature of the combined PET-CT devices. These 
scanners are now supplied by all the major manufacturers and are 
available at an increasing number of medical centers.
Since the execution of any PET scan requires an injection of 
radioactive material into the patient’s body, PET-CT examination 
obviously falls under the branch of nuclear medicine.
The topographic data is first of all used for attenuation cor-
rection purposes, allowing to shorten the scan time from 40 to 
15 minutes, compared to PET stand-alone homographs. However, 
attenuation correction may not represent all of the benefits of 
integrating CT with PET. The interpretation of PET-CT images can 
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be further improved by incorporating the morphological appear-
ances on CT into the image analysis.
In the ideal situation, the interpretation of the images should 
be performed by a multidisciplinary team, with a radiologist and 
nuclear medicine specialists working shoulder-to-shoulder [2, 3].
On the other hand, constant presence of a radiologist in 
a PET-CT laboratory is limited by several logistic and economic 
reasons. In clinical setting, the images interpretation is quite fre-
quently performed by a single nuclear medicine specialist only.
The number of physicians with a double specialization, in 
both radiology and nuclear medicine, is still very limited, and in 
most laboratories the nuclear medicine specialist usually uses the 
morphological data to localize the foci of uptake seen on the 
molecular imaging.
This solution has some limitations. Most nuclear medicine 
specialists actually working in PET laboratories have not received 
a specific training for the interpretation of topographic images, 
so there is potential risk of an insufficient definition of the exact 
localization of metabolic changes [4]. Moreover, a clinically relevant 
lesion seen on a CT scan but not showing significant radiotracer 
uptake is a relatively common finding and it represents a situation 
with no univocal conduct to follow. 
We analyzed two series of patients who underwent PET-CT 
examination for the same indication (evaluation of solitary pulmo-
nary nodule) and whose results were interpreted respectively by 
a nuclear medicine specialist alone and by a team with a nuclear 
medicine specialist and a radiologist. 
Materials and methods
PET-CT was performed on 58 consecutive patients referred 
from the Department of Thoracic Surgery from John Paul II Hos-
pital in Cracow because of a radiologically diagnosed solitary 
pulmonary nodule (SPN) with > 1 cm in diameter.
A histopathological specimen was obtained from 37 patients, 
by thoracothomy (36 patients) or transthoracic needle biopsy 
(1 patient). 7 patients had metastatic lesions at PET and did 
not undergo further invasive procedures. A histopathological 
specimen was not obtained from the remaining 21 patients for 
other reasons.
PET-CT tests were performed by using hybrid tomographs: 
Philips Gemini GXL (20 patients) or Siemens mCT (17 patients).
In 17 cases PET-CT images were evaluated by a single 
board-certified nuclear medicine specialist (group A), while for 
the successive 20 patients the image was analyzed by a team 
with a nuclear medicine specialist and a radiologist (group B).
In all cases the PET-CT description was performed in accord-
ance with the guidelines of the European Association of Nuclear 
Medicine [5] with a final conclusion reporting the probability of 
malignant nature for each described lesion.
Results
The histopathological examination demonstrated non-neo-
plastic character of 7/37 lesions (1 fibrotic nodule, 1 sarcoidosis, 
2 hamartomas and 3 inflammatory nodules), while the other le-
sions had neoplastic nature. The SUVmax value for the neoplastic 
lesions was 9.4 ± 4.8 while for the benign nodules it was 1.3 ± 0.7. 
Lesion diameter, metabolic and morphological features, clinical 
conclusion of the PET report and the results of histopathological 
examination are reported in Table 1 and 2 for groups A and B 
respectively. The overall values of sensitivity, specificity, accuracy, 
positive and negative predictive values for the groups are shown 
in Table 3.
Table 1. Group A results. From left: patient number, lesion diameter at histopathological report, SUVmax parameter measured in PET-CT 
examination, PET conclusion (cancer: lesion suspected to be of malignant nature; no cancer: lesion non-oncologically suspected) and 
results of histopathological examination
Group A   
Patient nr Lesion diameter SUV PET conclusion Histopathological results  
1 28 9 Cancer NSCLC squamous cell carcinoma  
2 31 2.6 Cancer NSCLC Adenocarcinoma   
3 32 9.6 Cancer NSCLC squamous cell carcinoma  
4 17 1.2 No cancer NSCLC squamous cell carcinoma  
5 45 5.7 Cancer NSCLC squamous cell carcinoma  
6 18 8.1 Cancer NSCLC squamous cell carcinoma  
7 23 0.3 No cancer Hamartoma    
8 30 16.9 Cancer NSCLC squamous cell carcinoma  
9 55 10.5 Cancer NSCLC squamous cell carcinoma  
10 40 11.1 Cancer NSCLC squamous cell carcinoma  
11 36 13.8 Cancer NSCLC squamous cell carcinoma  
12 40 3.8 Cancer NSCLC squamous cell carcinoma  
13 15 1.1 No cancer NSCLC Mucinous adenocarcinoma  
14 29 5.1 Cancer NSCLC Adenocarcinoma   
15 23 6.6 Cancer NSCLC Adenocarcinoma   
16 45 20 Cancer NSCLC squamous cell carcinoma  
17 30 7.7 Cancer Neuroendocrine tumor
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Our data is consistent with the data reported in the literature. 
The value of the diagnostic accuracy was approximately 90% 
for all the groups, without statistically significant differences. 
The lowest sensitivity and negative predictive values were found 
in group A (study described only by the specialist in nuclear 
medicine), while it was also the group where the highest speci-
ficity was observed. This fact is probably due to the reluctance 
of the nuclear medicine specialist to refer a nodule with faint 
FDG uptake as positive, even in the presence of radiological 
findings of malignancy, as for patient 4 and patient 13 in group 
A (Figure 1).
On the other hand, the accuracy was similar in both A and 
B groups.
Although the diagnostic performance of PET is improved by 
the use of CT to localize FDG-avid lesions anatomically, further 
benefits can be obtained by incorporating the morphological ap-
pearances on CT into the overall interpretation. A study by Nomori 
et al. [6] illustrates this concept particularly well by demonstrating 
that the diagnostic performance of PET in characterizing focal lung 
lesions is markedly affected by the CT appearances of the lesion. 
Other reports evidenced the need to analyze the PET-CT scan 
in an integrated and multidisciplinary way in order to maximize 
its diagnostic potential [7–9]. In our data this is quite evident for 
patient 20 in group B (Figure 2), where the radiological pattern of 
the mediastinal adenopathy allowed to make the suggestion of 
sarcoidosis, even in the presence of evident FDG uptake in the 
metabolic picture [10].
Finally, it is worth signalizing that several radiological 
changes caused by inflammation, emphysema, atelectasia or 
tuberculosis do not necessarily affect the metabolic image, but 
may be important for the referring doctor. An accurate radiological 
report gives a large amount of important information to the refer-
ring doctor, which will not necessarily be reported by the nuclear 
medicine specialist.
Table 2. Group B results. From left: patient number, lesion diameter at histopathological report, SUVmax parametermeasured in PET-CT 
examination, PET conclusion (cancer: lesion suspected to be of malignant nature; no cancer: lesion non-oncologically suspected) and 
results of histopathological examination
Group B   
Patient nr Lesion diameter SUV PET conclusion Histopathological results  
1 38 2.5 Cancer NSCLC squamous cell carcinoma 
2 37 6.5 Cancer TBC    
3 15 3.2 Cancer NSCLC large cell  
4 30 12 Cancer NSCLC squamous cell carcinoma 
5 20 1.1 No cancer Inflammation   
6 27 1.9 No cancer Solitary fibrous nodule  
7 32 12.9 Cancer NSCLC squamous cell carcinoma 
8 12 12.5 Cancer NSCLC Adenocarcinoma  
9 10 0.8 No cancer Hamartoma   
10 32 10.6 Cancer NSCLC squamous cell carcinoma 
11 27 6.7 Cancer NSCLC squamous cell carcinoma 
12 15 8.6 Cancer Small cel lung cancer  
13 70 13.7 Cancer NSCLC squamous cell carcinoma 
14 15 1.6 Cancer Neroendocrine tumor  
15 20 0.5 No cancer Inflammation   
16 40 9.7 Cancer NSCLC squamous cell carcinoma 
17 10 2.1 No cancer NSCLC squamous cell carcinoma 
18 60 18.1 Cancer NSCLC Adenocarcinoma  
19 50 14.5 Cancer NSCLC squamous cell carcinoma 
20 10 2.2 No cancer Sarcoidosis
 
Table 3. PET-CT Sensitivity, specificity, accuracy, positive and negative predictive values for both A and B groups
  Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Overall 90 85.70 96.6 66.60 89.10
Group A  85.70 100 100 33.30 88
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Conclusion
PET-CT is an accurate diagnostic method to assess the nature 
of solitary pulmonary nodules. The consultation with a radiologist 
does not substantially affect the PET-CT diagnostic accuracy. 
Nonetheless, given the importance of some radiological findings, 
it seems warranted that the PET-CT examination will be carefully 
examined by a radiologist or, in suborder, by a physician with ap-
propriate radiological skills.
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